Immunogenic compositions comprising
The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
1. A method for the treatment or reduction in the incidence or severity of clinical signs caused by Lawsonia intracellularis, Salmonella choleraesuis , and Erysipelothrix rhusiopathiae , said method comprising the steps of:
administering a composition containing antigenic components, wherein the antigenic components consist essentially of attenuated modified live Lawsonia intracellularis , an immunological active component of Salmonella choleraesuis , and an immunological active component of Erysipelothrix rhusiopathiae , to a non-human animal in need thereof, wherein said administration results in the treatment or reduction of clinical signs of Lawsonia intracellularis, Salmonella choleraesuis , and Erysipelothrix rhusiopathiae.
2. The method of claim 1 , wherein said attenuated modified live Lawsonia intracellularis , said immunological active component of Salmonella choleraesuis , and said immunological active component of Erysipelothrix rhusiopathiae are administered on the same day.
3. The method of claim 1 , wherein said attenuated modified live Lawsonia intracellularis , said immunological active component of Salmonella choleraesuis , and said immunological active component of Erysipelothrix rhusiopathiae are administered at the same time.
4. The method of claim 1 , wherein at least two of said attenuated modified live Lawsonia intracellularis , said immunological active component of Salmonella choleraesuis , and said immunological active component of Erysipelothrix rhusiopathiae are combined together prior to administration thereof.
5. The method of claim 1 , wherein said clinical signs include lesions caused by Lawsonia intracellularis , lesions caused by Erysipelothrix rhusiopathiae , and clinical signs caused by virulent Salmonella cholaraesuis.
6. The method of claim 1 , wherein said attenuated modified live Lawsonia intracellularis is effective for reducing the incidence of or lessening the severity of porcine proliferative enteropathy caused by Lawsonia intracellularis.
7. The method of claim 1 , wherein said immunological active component of Salmonella choleraesuis further comprises attenuated Salmonella choleraesuis and wherein said attenuated Salmonella choleraesuis is effective for reducing the incidence of or lessening the severity of infections caused by Salmonella choleraesuis.
8. The method of claim 1 , wherein said immunological active component of Erysipelothrix rhusiopathiae further comprises attenuated Erysipelothrix rhusiopathiae and wherein said attenuated Erysipelothrix rhusiopathiae is effective for reducing the incidence of or lessening the severity of infections caused by Erysipelothrix rhusiopathiae.
9. The method of claim 1 , wherein said composition further comprises a veterinary-acceptable carrier.
10. The method of claim 9 , wherein said veterinary-acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and combinations thereof.
11. A method for treating or reducing the incidence or severity of clinical signs of diseases caused by Lawsonia intracellularis and two or more further swine pathogenic microorganisms, said two or more further swine pathogenic microorganisms including Salmonella choleraesuis and Erysipelothrix rhusiopathiae , said method comprising the steps of:
administering a composition containing antigenic components, where the antigenic components consist essentially of avirulent modified live Lawsonia intracellularis to a non-human animal in need thereof together with an immunological active component of Salmonella choleraesuis and an immunological active component of Erysipelothrix rhusiopathiae , to an animal in need thereof, wherein said administration results in the treatment or reduction in the incidence or severity of clinical signs of Lawsonia intracellularis, Salmonella choleraesuis , and Erysipelothrix rhusiopathiae.
12. The method of claim 11 , wherein said administration of said avirulent modified live Lawsonia intracellularis , said immunological active component of Salmonella choleraesuis and said immunological active component of Erysipelothrix rhusiopathiae occurs on the same day.
13. The method of claim 11 , wherein said administration of said avirulent modified live Lawsonia intracellularis , said immunological active component of Salmonella choleraesuis and said immunological active component of Erysipelothrix rhusiopathiae occurs at the same time.
14. The method of claim 11 , wherein at least two of said avirulent modified live Lawsonia intracellularis , said immunological active component of Salmonella choleraesuis and said immunological active component of Erysipelothrix rhusiopathiae are combined together prior to said administration.
15. The method of claim 11 , wherein said clinical signs include lesions caused by Lawsonia intracellularis , lesions caused by Erysipelothrix rhusiopathiae , and clinical signs caused by virulent Salmonella cholaraesuis.
16. The method of claim 11 , wherein said avirulent modified live Lawsonia intracellularis is effective for reducing the incidence of or lessening the severity of porcine proliferative enteropathy caused by L. intracellularis.
17. The method of claim 11 , wherein said immunological active component of Salmonella choleraesuis further comprises attenuated Salmonella choleraesuis and wherein said attenuated Salmonella choleraesuis is effective for reducing the incidence of or lessening the severity of infections caused by Salmonella choleraesuis.
18. The method of claim 11 , wherein said immunological active component of Erysipelothrix rhusiopathiae further comprises attenuated Erysipelothrix rhusiopathiae and wherein said attenuated Erysipelothrix rhusiopathiae is effective for reducing the incidence of or lessening the severity of infections caused by Erysipelothrix rhusiopathiae.
19. The method of claim 11 , wherein said composition further comprises a veterinary-acceptable carrier.
20. The method of claim 1 , wherein said veterinary-acceptable carrier is selected from the group consisting of solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and combinations thereof.
21. A method for the treatment or reduction in the incidence or severity of clinical signs caused by Lawsonia intracellularis, Salmonella choleraesuis , and Erysipelothrix rhusiopathiae , said method consisting essentially of the steps of:
administering a composition containing antigenic components, wherein the antigenic components consist essentially of attenuated modified live Lawsonia intracellularis , an immunological active component of Salmonella choleraesuis , and an immunological active component of Erysipelothrix rhusiopathiae to a non-human animal in need thereof, wherein said administration results in the treatment or reduction of clinical signs of Lawsonia intracellularis, Salmonella choleraesuis , and Erysipelothrix rhusiopathiae.